My latest Guardian column is "Why all pharmaceutical research should be made open access," and it makes the wider case for open access, beyond the obvious truth that publicly funded work should be available to the public:
One of the strongest arguments for public access in scholarly and scientific publication is the "public debt" argument: if the public pays you to do research, the research should belong to the public. That's a good argument, but it's not the whole story. For one thing, it's vulnerable to the "public-private partnership" counterargument, which goes, "Ah, yes, but why not ensure that the public gets a maximum dividend on its spending by charging lots of money for access to publicly funded research and returning the profit to the research sector?" I think this argument is rubbish, as do most economists who have studied the question.
The public good of freely accessible, unencumbered research generates more economic value for the public than the quick-hit sugar-rush you get from charging the public on the way in and again on the way out. This has held true in many sectors, though the canonical example is the massive public return from the US Geological Survey's freely usable maps, which have generated a fortune that makes the ransoms collected by the Ordnance Survey on its maps of the UK look like a pittance.
That's why Goldacre's work is important to this discussion. The reason pharma companies should be required to publish their results isn't that they've received a public subsidy for the research. Rather, it is because they are asking for a governmental certification saying that their products are fit for consumption, and they are asking for regulatory space to allow doctors to write prescriptions for those products. We need them to disclose their research – even if doing so undermines their profits – because without that research, we can't know if their products are fit for use.
Why all pharmaceutical research should be made open access
CSIR-Tech is the commercial arm of the Indian government’s Council of Scientific and Industrial Research; after spending ₹50 crore (about USD7.6M) pursuing more than 13,000 “bio-data patents” (patents of no real value save burnishing the credentials of the scientists whose names appear on them), they have run out of money and shut down.
Troy Hunt, proprietor of the essential Have I Been Pwned (previously) sets out the hard lessons learned through years of cataloging the human costs of breaches from companies that overcollected their customers’ data; undersecured it; and then failed to warn their customers that they were at risk.
The World Wide Web Consortium has announced that its members have until April 19 to weigh in on whether the organization should publish Encrypted Media Extensions, its DRM standard for web video, despite the fact that this would give corporations the new right to sue people who engaged in legal activity, from security researchers who […]
What could be more fun than a slingshot that shoots tiny airplanes? A slingshot that shoots tiny glowing airplanes of course! These toy planes are outfitted with ultra-bright LEDs, so you can fly all night without losing them in the trees.Whether you are a regular-sized child, or an overgrown adult one, these light-up flyers offer […]
You know the drill. You go to the dentist and they ask you how often you floss. You lie through your teeth and say, “every day!” (Bonus points if you have some cilantro or chives stuck in your gums from lunch). You don’t want to keep up the charade any longer, but rubbing that tiny strand […]
The Raspberry Pi Foundation has done outstanding work packing a fully capable desktop computer into a package the size of a deck cards—especially one that only costs $35. But if you already have a working laptop, why should you care? Oh, how much you have to learn. Besides operating well as a compact digital media hub, […]